One study identified EYA2 as a potential target for molecular therapy in a subtype of acute myeloid leukemia (Ono et al., 2017), whereas OCSTAMP mRNA levels were connected to multiple myeloma (Wang et al., 2020) and TP53RK expression is inversely correlated with multiple myeloma survival (Hideshima et al., 2017). Here, EYA2 is linked to plasma cell myeloma.